Regencell Bioscience Holdings (RGC) IPO Opens 26% Higher

Go back to Regencell Bioscience Holdings (RGC) IPO Opens 26% Higher

Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

July 15, 2021 5:59 PM EDT

HONG KONG--(BUSINESS WIRE)-- Regencell Bioscience Holdings Limited (NASDAQ: RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 16, 2021 under the ticker symbol RGC.

Regencell... More